Qiagen (NYSE:QGEN – Get Free Report) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.
Several other research firms have also weighed in on QGEN. Citigroup lowered their target price on Qiagen from $55.00 to $38.00 and set a “neutral” rating on the stock in a report on Wednesday. UBS Group set a $52.00 price objective on Qiagen in a research report on Monday, February 9th. JPMorgan Chase & Co. reduced their price objective on Qiagen from $60.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday. Barclays set a $38.00 price objective on Qiagen and gave the company an “equal weight” rating in a research report on Wednesday. Finally, Wall Street Zen downgraded Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $47.09.
Check Out Our Latest Analysis on QGEN
Qiagen Trading Up 2.9%
Qiagen (NYSE:QGEN – Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. The company had revenue of $540.42 million for the quarter, compared to analyst estimates of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.Qiagen’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.61 earnings per share. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. As a group, sell-side analysts forecast that Qiagen will post 2.44 EPS for the current fiscal year.
Hedge Funds Weigh In On Qiagen
A number of large investors have recently modified their holdings of QGEN. United Services Automobile Association purchased a new position in shares of Qiagen in the 1st quarter worth about $239,000. Prudential Financial Inc. raised its holdings in shares of Qiagen by 74.9% during the 2nd quarter. Prudential Financial Inc. now owns 8,873 shares of the company’s stock valued at $426,000 after buying an additional 3,799 shares during the period. Invesco Ltd. raised its holdings in shares of Qiagen by 123.7% during the 2nd quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock valued at $48,350,000 after buying an additional 556,387 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Qiagen by 226.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock valued at $125,000 after buying an additional 1,802 shares during the period. Finally, First Trust Advisors LP purchased a new stake in shares of Qiagen during the 2nd quarter valued at about $3,639,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.
Qiagen News Summary
Here are the key news stories impacting Qiagen this week:
- Positive Sentiment: Baird upgraded QGEN from “hold” to “strong-buy” and set a $43 price target, providing fresh buy-side support and a near-term bullish catalyst. Baird upgrades Qiagen NV (QGEN)
- Neutral Sentiment: Qiagen announced the date for publication of its 2025 annual financial report — a routine disclosure that reduces uncertainty but is unlikely to change the near-term outlook by itself. Qiagen Sets Date for Publication of 2025 Annual Financial Report
- Neutral Sentiment: JPMorgan cut its price target to $45 (from $60) but retained an “overweight” rating — a mixed signal: lower upside in JPM’s model but continued conviction in medium-term outperformance. Qiagen (NYSE:QGEN) Price Target Lowered to $45.00 at JPMorgan Chase & Co.
- Neutral Sentiment: Citigroup trimmed its target to $38 and moved to a “neutral” rating, narrowing analyst-driven upside expectations and adding to mixed analyst sentiment. Citigroup lowers Qiagen price target
- Negative Sentiment: Levi & Korsinsky announced an investigation into Qiagen over potential fraud claims — a reputational and litigation risk that can weigh on the stock until clarified. Ongoing Investigation into Qiagen N.V. (QGEN)
- Negative Sentiment: After-hours trading reacted negatively to management’s guidance cut tied to weaker-than-expected tuberculosis (TB) test demand — this operational weakness is a direct driver of near-term revenue risk. QGEN stock slumps after-hours on guidance cut tied to weak TB test demand
- Negative Sentiment: Reports note QGEN shares hit multi‑year weakness as geopolitical headwinds in the Middle East weighed on Q1 results — an external demand shock that contributed to the recent pullback. Qiagen NV (QGEN) Falls to 7-Year Low as MidEast Tensions Drag Q1
About Qiagen
Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.
The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.
Further Reading
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
